Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128278 | 0.92 | CYP3A4 (0.52) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7131234 | 0.91 | CYP3A4 (0.53) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL20012357 | 0.91 | CYP3A4 (0.53) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7122259 | 0.91 | CYP3A4 (0.51) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7131157 | 0.91 | CYP3A4 (0.51) | CYP3A4SLC29A1HPRT1CYP2D6 | |
| SCHEMBL7127594 | 0.90 | CYP3A4 (0.52) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL6847582 | 0.90 | CYP3A4 (0.56) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7127111 | 0.90 | CYP3A4 (0.49) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7127530 | 0.88 | CYP3A4 (0.56) | CYP3A4SLC29A1HPRT1CYP1A2CYP2D6 | |
| SCHEMBL7769563 | 0.87 | SLC29A1 (0.46) | CYP3A4SLC29A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-12 | — | — | US | claimed |
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109498-A1 | Antiviral agent for drug-resistant virus | TPMT, MTAP, TYMP | CYP3A4 977/4885SLC29A1 5/4885HPRT1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.